New oral anticoagulant-induced bleeding: Clinical presentation and management

Clinics in Laboratory Medicine

Volumn 34, Issue 3, 2014, Pages 575-586

  Levy, Jerrold H ^a   Levi, Marcel ^b  

^a DUKE UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anticoagulation; Bleeding; Hemorrhage; New oral anticoagulants; Reversal; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 9 COMPLEX; CLOPIDOGREL; DABIGATRAN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; PRT 064445; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANTICOAGULANT THERAPY; ANTICOAGULATION REVERSAL; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CASE STUDY; CONTINUOUS HEMODIALYSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HEPARINIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA TRANSFUSION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; ANIMAL; CHEMICALLY INDUCED; EVIDENCE BASED MEDICINE; HEMORRHAGE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RISK;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; EVIDENCE-BASED MEDICINE; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK;

EID: 84906940152     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.06.004     Document Type: Review

References (71)

1. Naccarelli G.V., Varker H., Lin J., et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009, 104(11):1534-1539.
2. Heit J.A., Cohen A.T., Anderson F.A. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005, 106:910.
3. Nutescu E.A., Shapiro N.L., Chevalier A., et al. Apharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 2005, 72(Suppl 1):S2-S6.
4. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
5. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
6. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
7. Büller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. NEngl J Med 2012, 366:1287-1297.
8. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. NEngl J Med 2009, 361:2342-2352.
9. Southworth M.R., Reichman M.E., Unger E.F. Dabigatran and postmarketing reports of bleeding. NEngl J Med 2013, 368(14):1272-1274.
10. U.S. Food and Drug Administration. Pradaxa (dabigatran etexilate meslate): drug safety communication - safety review of post-market reports of serious bleeding events. 2012. Available at: Accessed August 6, 2013. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm282820.htm.
11. Berger R., Salhanick S.D., Chase M., et al. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med 2013, 61(4):475-479.
12. Dickneite G., Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thromb Haemost 2014, 111(2):189-198.
13. Levine M.N., Raskob G., Beyth R.J., et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(Suppl 3):287S-310S.
14. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006, 114(8):774-782.
15. IMS. IMS data US National Prescription Audit; MAT (moving annual total) 2011-2012.
16. Budnitz D.S., Shehab N., Kegler S.R., et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007, 147(11):755-765.
17. Budnitz D.S., Lovegrove M.C., Shehab N., et al. Emergency hospitalizations for adverse drug events in older Americans. NEngl J Med 2011, 365(21):2002-2012.
18. Wysowski D.K., Nourjah P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167(13):1414-1419.
19. Stead L.G., Jain A., Bellolio M.F., et al. Effect of anticoagulant and antiplatelet therapy in patients with spontaneous intra-cerebral hemorrhage: does medication use predict worse outcome?. Clin Neurol Neurosurg 2010, 112(4):275-281.
20. Flaherty M.L., Tao H., Haverbusch M., et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008, 71(14):1084-1089.
21. Broderick J.P., Brott T.G., Duldner J.E., et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993, 24(7):987-993.
22. Huhtakangas J., Tetri S., Juvela S., et al. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 2011, 42(9):2431-2435.
23. Rosand J., Eckman M.H., Knudsen K.A., et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004, 164(8):880-884.
24. Azoulay L., Dell'Aniello S., Simon T., et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost 2013, 109(3):431-439.
25. Gomes T., Mamdani M.M., Holbrook A.M., et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 2013, 185(2):E121-E127.
26. Desai J., Granger C.B., Weitz J.I., et al. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc 2013, 78(2):227-239.
27. Capodanno D., Capranzano P., Giacchi G., et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol 2013, 167(4):1237-1241.
28. Miller C.S., Grandi S.M., Shimony A., et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012, 110(3):453-460.
29. Providencia R., Albenque J.P., Combes S., et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2013, 100(4):324-335.
30. Australian Therapeutic Goods Administration (TGA). Dabigatran (Pradaxa) and risk of bleeding: information for health professionals. 2013. Available at: Accessed September 3, 2013. http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm.
31. European Medicines Agency (EMA). European Medicines Agency updates patient and prescriber information for Pradaxa. 2012. Available at: Accessed September 4, 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/05/news_detail_001518.jsp%26mid=WC0b01ac058004d5c1.
32. Boehringer Ingelheim. Boehringer Ingelheim announces agreement to studyreal-world use of oral anticoagulants. 2013. Available at: Accessed September 9, 2013. http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2013/08-15-13-boehringer-ingelheim-announces-agreement-study-real-world-use-oral-anticoagulants.html.
33. Board of the German Medical Association Cross-sectional guidelines for therapy with blood components and blood derivatives; plasma for therapeutic use. Transfus Med Hemother 2009, 26:388-397.
34. Holbrook A., Schulman S., Witt D.M., et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e152S-e184S.
35. Keeling D., Baglin T., Tait C., et al. Guidelines on oral anticoagulation with warfarin- fourth edition. Br J Haematol 2011, 154:311-324.
36. Pernod G., Godier A., Gozalo C., et al. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010, 126:e167-e174.
37. Spahn D.R., Bouillon B., Cerny V., et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013, 17:R76.
38. Sarode R., Milling T.J., Refaai M.A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013, 128(11):1234-1243.
39. Heidbuchel H., Verhamme P., Alings M., et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013, 15:625-651.
40. Huisman M.V., Lip G.Y., Diener H.C., et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012, 107:838-847.
41. Levy J.H., Faraoni D., Spring J.L., et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013, 118:1466-1474.
42. Pengo V., Crippa L., Falanga A., et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011, 106:868-876.
43. Turpie A.G., Kreutz R., Llau J., et al. Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2012, 108:876-886.
44. Pernod G., Albaladejo P., Godier A., et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013, 106(6-7):382-393.
45. Ageno W., Gallus A.S., Wittkowsky A., et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl 2):e44S-e88S.
46. Kaatz S., Kouides P.A., Garcia D.A., et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012, 87(Suppl 1):S141-S145.
47. Fawole A., Daw H.A., Crowther M.A. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013, 80(7):443-451.
48. Queensland Health. Guideline for managing patients on dabigatran (Pradaxa®). 2013. Available at: Accessed September 9, 2013. http://www.health.qld.gov.au/qhcss/mapsu/documents/dabigatran_info.pdf.
49. Peacock W.F., Gearhart M.M., Mills R.M. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol 2012, 35(12):730-737.
50. Pollack C.V. Managing bleeding in anticoagulated patients in the emergency care setting. JEmerg Med 2013, 45(3):467-477.
51. Miesbach W., Seifried E. New direct oral anticoagulants - current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012, 108(4):625-632.
52. Marlu R., Hodaj E., Paris A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover exvivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224.
53. Perzborn E., Gruber A., Tinel H., et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013, 110:162-172.
54. Zhou W., Zorn M., Nawroth P., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013, 44:771-778.
55. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
56. Levi M., Moore T., Castillejos C.F., et al. Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban (2013 ISTH abstracts). JThromb Haemost 2013, 11(Suppl s2):167.
57. Baumann Kreuziger L.M., Reding M.T. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Thromb Res 2013, 132(2):e161-e163.
58. Dager W.E., Gosselin R.C., Roberts A.J. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013, 41(5):e42-e46.
59. Diaz M.Q., Borobia A.M., Nunez M.A., et al. Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department. Haematologica 2013, 98(11):e143-e144.
60. Dumkow L.E., Voss J.R., Peters M., et al. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm 2012, 69(19):1646-1650.
61. Harinstein L.M., Morgan J.W., Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. JPharm Pract 2013, 26(3):264-269.
62. Khadzhynov D., Wagner F., Formella S., et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013, 109(4):596-605.
63. Cano E.L., Miyares M.A. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012, 10(2):160-163.
64. Warkentin T.E., Margetts P., Connolly S.J., et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012, 119(9):2172-2174.
65. van Ryn J., Litzenburger T., Waterman A., et al. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in invitro and invivo models. JThromb Haemost 2011, 9(Suppl 2):1-970.
66. Lu G., DeGuzman F.R., Hollenbach S.J., et al. Aspecific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, 19:446-451.
67. Prandoni P., Noventa F., Ghirarduzzi A., et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007, 92(2):199-205.
68. Bayer Pharma AG. Xarelto® - Summary of product characteristics. Available at: Accessed September 10, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
69. Boehringer Ingelheim. Pradaxa® - Summary of product characteristics. Available at: Accessed September 10, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/05/WC500127777.pdf.
70. Bristol-Myers Squibb. Eliquis® - Summary of product characteristics. Available at: Accessed September 10, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf.
71. Schulman S., Crowther M.A. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012, 119(13):3016-3023.